Table 2.
Final follow-up post-procedural parameters of blood pressure, renal function, blood lowering medications, glycaemic and biochemical tests, and stent patency in MACCE-RRT (+) vs. MACCE-RRT (−) patients.
| Final Follow-Up Post-Procedural Parameters | MACCE-RRT (−) N = 47 |
MACCE-RRT (+) N = 46 |
p-Value |
|---|---|---|---|
| Fasting glucose (mmol/L), mean (SD) | 7.13 (3.25) | 8.10 (3.72) | 0.140 |
| HbA1C (%), mean (SD) | 6.3 (2.2) | 7.8 (2.8) | 0.010 |
| Maintained target goal for T2DM control, n (%) | 27 (57.4) | 12 (26.1) | 0.002 |
| LDL-cholesterol (mmol/L), mean (SD) | 2.48 (0.86) | 2.77 (1.17) | 0.112 |
| Systolic blood pressure, mmHg, mean (SD) | 136.7 (15.8) | 147.8 (25.8) | 0.006 |
| Diastolic blood pressure, mmHg, mean (SD) | 74.4 (12.3) | 80.8 (13.3) | 0.009 |
| Optimal SBP target goal (120–130 mmHg) | 26 (55.3) | 15 (32.6) | 0.027 |
| Optimal DBP target goal (70–80 mmHg) | 37 (78.7) | 24 (52.2) | 0.007 |
| Number of blood lowering medications, mean (SD) | 3.70 (1.2) | 3.87 (1.47) | 0.273 |
| Serum creatinine level, µmol/L, mean (SD) | 117.3 (51.9) | 150.1 (69.4) | 0.006 |
| eGFR, mL/min/m2, mean (SD) | 54.4 (19.2) | 47.2 (25.4) | 0.172 |
| eGFR < 45 mL/min/m2, n (%) | 16 (34) | 28 (60.9) | 0.029 |
| stage 1 (eGFR > 90 mL/min/m2), n (%) | 3 (4.3) | 5 (10.9) | - |
| stage 2 (eGFR: 60–89 mL/min/m2), n (%) | 15 (31.9) | 5 (10.9) | - |
| stage 3A (eGFR: 45–59 mL/min/m2), n (%) | 13 (27.7) | 8 (17.4) | - |
| stage 3B (eGFR: 30–44 mL/min/m2) | 13 (27.7) | 16 (34.8) | - |
| stage 4 (eGFR: 15–29 mL/min/m2), n (%) | 3 (6.3) | 7 (15.2) | - |
| stage 5 (eGFR < 15 mL/min/m2), n (%) | 0 (0) | 5 (10.9) | - |
| In-stent restenosis of index lesion, n (%) | 6 (12.8) | 18 (39.1) | 0.004 |
| Renal replacement therapy, n (%) | - | 10 (21.7) * | - |
| Transient (peri-procedural) RRT, n (%) | - | 4 | - |
| Permanent RRT, n (%) | - | 6 | - |
| Major adverse cardiac and cerebral event, n (%) | - | 41 (89.1) * | - |
| Cardiovascular death, n (%) | - | 17 (37) * | - |
| Non-fatal stroke, n (%) | - | 11 (23.9) * | - |
| Non-fatal myocardial infarction, n (%) | - | 18 (39.1) * | - |
* some patients had both major cardiac and cerebral event and renal replacement therapy.